More Company News

Allergy Therapeutics

FY20 preliminary results
23 Sep 2020Read More

Allergy Therapeutics

Start of pilot study for new depression treatment protocol in Kuopio University Hospital
22 Sep 2020Read More

Allergy Therapeutics

H120 results for six months ended June 2020
21 Sep 2020Read More

Allergy Therapeutics

Surufatinib Phase III data in NETs at ESMO 2020 and Publication in The Lancet Oncology
20 Sep 2020Read More

Allergy Therapeutics

Acceptance of second China NDA for surufatinib in pNET
17 Sep 2020Read More

Allergy Therapeutics

Two NBS System upgrade orders in the US
16 Sep 2020Read More

Allergy Therapeutics

H120 interim results
16 Sep 2020Read More

Allergy Therapeutics

Approval to commence Phase II bemcentinib trial for COVID-19 in South Africa
11 Sep 2020Read More

Allergy Therapeutics

Nexstim pre-surgical mapping technology covered in 100+ scientific articles
10 Sep 2020Read More

Allergy Therapeutics

New research collaboration with Jazz Pharmaceuticals
09 Sep 2020Read More

1 2 3 4 … 45
Return to Allergy Therapeutics
© 2019-20 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).